Bristol-Myers Squibb Company (BMY)

In the past six months, Bristol Myers Squibb's stock has been influenced by several events. Positive developments included Q2 2025 earnings beat, raised guidance, regulatory approvals, positive trial results, and new product options. Negative developments included Q1 2025 revenue decline, Cobenfy trial failure, increased short interest, patent expirations, and underperformance of key assets. The stock price increased by 10.99% between July 22, 2024, and July 18, 2025. As of July 21, 2025, the stock was down 0.49% over the past 30 days and up 9.42% over the past 12 months.

Information directly detailing the seasonality of demand for Bristol Myers Squibb's specific products and services is limited. However, some financial data suggests operational fluctuations that might indirectly indicate some degree of seasonality. Accounts payable have shown fluctuations with some cyclical patterns, and inventory turnover has also varied. One earnings call transcript mentions "product seasonality we expect to see in..." but does not elaborate on the specific patterns. Stock seasonality analysis is available, which highlights recurring trends in asset performance over specific months, but this relates to stock price movements rather than inherent product demand.

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases, operating in the Healthcare sector, specifically in the Drug Manufacturers - General and Biopharmaceutical industries. The company focuses on key therapeutic areas, including oncology, hematology, immunology, cardiovascular disease, neuroscience, and fibrotic diseases. Major products include Opdivo, Yervoy, Sprycel, Krazati, Reblozyl, Sotyktu, Orencia, Eliquis, Plavix, Avapro/Avalide, Reyataz, Sustiva, Baraclude and Cobenfy. Bristol Myers Squibb has also expanded its portfolio through strategic acquisitions, including Mirati Therapeutics and Karuna Therapeutics in 2024.

Bristol Myers Squibb has a significant global presence, operating in over 60 countries with major research hubs in North America, Europe, and Asia, and manufacturing facilities across key regions. In the U.S., its R&D hubs are situated in Central New Jersey, the San Francisco Bay Area, and Cambridge, Massachusetts. Manufacturing units are located in the U.S., Switzerland, Puerto Rico, Ireland, and the Netherlands. The United States is a primary market, accounting for a substantial portion of its total revenue, ranging from approximately 70% to 97% in recent fiscal years.

In the past year, Bristol Myers Squibb's brand reputation has seen both positive and challenging developments. Positive developments include advancing its pipeline, securing regulatory milestones, the U.S. approval of Opdivo Qvantig, the U.S. launch of Cobenfy in late 2024, a positive CHMP opinion for a hepatocellular carcinoma treatment, and strong sales growth across numerous commercial products. Negative developments include the failure of Cobenfy to meet endpoints in a study in April 2025, historical legal challenges, and criticism regarding its reliance on a small number of blockbuster drugs.

Bristol Myers Squibb has a diverse ownership structure. Institutional shareholders hold a significant majority of the stock, with approximately 78.30% or 80.79% of shares held by institutions. Individual investors hold around 21.33% or 50.89%, while insiders hold a small percentage, approximately 0.37% or 0.05%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., JPMorgan Chase & Co., State Street Corp, Capital International Investors, Charles Schwab Investment Management Inc., and Geode Capital Management, Llc.